Emerging Therapeutic Targets in Ovarian Cancer

ISBN-13: 9781489982339 / Angielski / Miękka / 2014 / 291 str.

Stan Kaye;Robert Brown;Hani Gabra

Opis

This book offers a progress report on efforts to meet the challenges faced by ovarian cancer patients and their doctors. It provides a current perspective on therapeutic developments as a partnership between laboratory-based and clinical-based researchers.

Spis treści

1 Existing treatment for ovarian cancer: recent advances and description of unmet needs S Banerjee M Bookman M Gore 2 Discovery of novel targets J Farley M Birrer 3 Anti-angiogenesis – update on its application in ovarian cancer J Hasan G Jayson 4 Targeting the PI3K/AKT pathway E Stronach A Cheraghchi-Bashi M Chen H Gabra 5 Inhibition of the SRC oncogene; potential in ovarian cancer LY Han AK Sood 6 Tumour specific synthetic lethality; targeting BRCA gene dysfunction TA Yap SB Kaye A Ashworth A Tutt 7 Inhibition of cytokines and chemokines in ovarian cancer J Coward F Balkwill 8 Potential for inhibition of membrane receptors (EGF, IGF, c-MET, and others) LP Martin JJ Perkins R Schilder 9 An epigenetic approach to ovarian cancer R Brown N Chapman-Rothe R Glasspool 10 Immunotherapy; update on its application in ovarian cancer S Ghaem-Maghami M Gore 11 Ovarian cancer progenitor/stem cells; therapeutic potential S Murphy A Berchuck 12 Potential for α-folate receptor targeted treatment for ovarian cancer CHM Ng A Jackman 13 New insights into tubulin binders J Brenton

Blurb

Despite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging. In this text, all these areas are covered by experts in the field. Each chapter provides up-to-date coverage of clinical information, prefaced by a description of the rational basis for the selection of each target area and consideration of biomarkers that can be used to aid clinical evaluation. The four editors work together within the Ovarian Cancer Action collaborative research programme in London and they bring a wealth of laboratory and clinical expertise to this topic. The text should provide an invaluable source of reference for clinical and laboratory-based researchers working to meet the challenges of ovarian cancer.